Net Cash Provided by (Used in) Financing Activities in USD of Checkpoint Therapeutics, Inc. from 2015 to Q1 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
Checkpoint Therapeutics, Inc. quarterly and annual Net Cash Provided by (Used in) Financing Activities history and change rate from 2015 to Q1 2025.
  • Checkpoint Therapeutics, Inc. Net Cash Provided by (Used in) Financing Activities for the quarter ending 31 Mar 2025 was $38,124,000, a 198% increase year-over-year.
  • Checkpoint Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2024 was $32,777,000, a 19% decline from 2023.
  • Checkpoint Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2023 was $40,450,000, a 172% increase from 2022.
  • Checkpoint Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2022 was $14,887,000, a 63% decline from 2021.
Source SEC data
View on sec.gov
Net Cash Provided by (Used in) Financing Activities, Quarterly (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Quarterly Change (%)
Net Cash Provided by (Used in) Financing Activities, Annual (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Annual Change (%)

Checkpoint Therapeutics, Inc. Quarterly Net Cash Provided by (Used in) Financing Activities (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q1 2025 $38,124,000 +$25,337,000 +198% 01 Jan 2025 31 Mar 2025 10-Q 13 May 2025 2025 Q1
Q1 2024 $12,787,000 +$5,978,000 +88% 01 Jan 2024 31 Mar 2024 10-Q 13 May 2025 2025 Q1
Q1 2023 $6,809,000 +$462,000 +7.3% 01 Jan 2023 31 Mar 2023 10-Q 10 May 2024 2024 Q1
Q1 2022 $6,347,000 -$17,571,000 -73% 01 Jan 2022 31 Mar 2022 10-Q 15 May 2023 2023 Q1
Q1 2021 $23,918,000 +$23,974,000 01 Jan 2021 31 Mar 2021 10-Q 12 May 2022 2022 Q1
Q1 2020 $56,000 -$411,000 -116% 01 Jan 2020 31 Mar 2020 10-Q 07 May 2021 2021 Q1
Q1 2019 $355,000 -$20,490,000 -98% 01 Jan 2019 31 Mar 2019 10-Q 07 May 2020 2020 Q1
Q1 2018 $20,845,000 +$20,845,000 01 Jan 2018 31 Mar 2018 10-Q 10 May 2019 2019 Q1
Q1 2017 $0 01 Jan 2017 31 Mar 2017 10-Q 10 May 2018 2018 Q1

Checkpoint Therapeutics, Inc. Annual Net Cash Provided by (Used in) Financing Activities (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $32,777,000 -$7,673,000 -19% 01 Jan 2024 31 Dec 2024 10-K 28 Mar 2025 2024 FY
2023 $40,450,000 +$25,563,000 +172% 01 Jan 2023 31 Dec 2023 10-K 28 Mar 2025 2024 FY
2022 $14,887,000 -$25,382,000 -63% 01 Jan 2022 31 Dec 2022 10-K 22 Mar 2024 2023 FY
2021 $40,269,000 +$9,023,000 +29% 01 Jan 2021 31 Dec 2021 10-K 31 Mar 2023 2022 FY
2020 $31,246,000 +$5,791,000 +23% 01 Jan 2020 31 Dec 2020 10-K 28 Mar 2022 2021 FY
2019 $25,455,000 -$3,120,000 -11% 01 Jan 2019 31 Dec 2019 10-K 12 Mar 2021 2020 FY
2018 $28,575,000 +$28,575,000 01 Jan 2018 31 Dec 2018 10-K 11 Mar 2020 2019 FY
2017 $0 +$2,222,000 01 Jan 2017 31 Dec 2017 10-K 18 Mar 2019 2018 FY
2016 $2,222,000 -$56,273,000 -104% 01 Jan 2016 31 Dec 2016 10-K 16 Mar 2018 2017 FY
2015 $54,051,000 01 Jan 2015 31 Dec 2015 10-K 16 Mar 2018 2017 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.